All In Biotech

Drug Trial Radar · NCT04056325

Efficacy, Safety, and PK of Ascending Dosages of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis

Efficacy, Safety and Pharmacokinetics of Ascending Dosages of Moxidectin Alone and in Comparison to Ivermectin Against Strongyloides Stercoralis in Adults: a Randomized Controlled Trial

Last checked: Nov 19, 2026Latest source record: Dec 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 617 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

617

Actual

Start

Nov 27, 2019

Primary completion

Apr 30, 2021

Study completion Apr 30, 2021

Sponsor

Lead sponsor
Jennifer KeiserAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Public Health, Vientiane, Laos
First posted
Aug 14, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a phase 2, blinded and randomized clinical trial. The phase 2a trial is single blinded and conducted in Lao, while the phase 2b trial is double-blinded and conducted in Lao and Cambodia. The study aims at providing evidence on effective doses and safety of moxidectin in adults against infection with S. stercoralis in Laos (trial 2a) and efficacy and safety of moxidectin compared to ivermectin in adults against infection with S. stercoralis in Laos and Cambodia (trial 2b). The efficacy of the treatment will be assessed by collecting three stool samples once pre-treatment and once 21 days post-treatment. The stool samples will be analyzed by a quantitative Baermann assay.

Conditions

  • Strongyloides Stercoralis Infection

Interventions

  • MoxidectinDrug

    Monotherapy, oral administration, single dose, fixed dose

  • IvermectinDrug

    Monotherapy, oral administration, single dose, weight dependent

  • Placebo oral tabletDrug

    Monotherapy, oral administration, single dose, matching number of tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Observed Cure Rate Against Strongyloides StercoralisTime frame: Phase 2a: 21-28 days after treatment; phase 2b: 14-21 days after treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Institute of Public Health

    Vientiane, Laos

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.